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 Conclusions: IL-4 and IL-13 induce bronchial hyperreactivity 
by changing the Ca 2+  homeostasis of ASMC. These effects 
are counteracted by IL-13R  2. The biological significance of 
IL-13R  2 might be a protective function by regulating IL-13- 
and IL-4-mediated signal transduction and thereby limiting 
pathological alterations in Th2-mediated inflammatory dis-
eases. 
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 Introduction 
 Asthma is a complex lung disease characterized by 
bronchial hyperreactivity (BHR) and airway inflamma-
tion, which is dominated by Th2 lymphocytes. Interleu-
kin-4 (IL-4) and interleukin-13 (IL-13) are proinflamma-
tory cytokines that are released by Th2 lymphocytes  [1, 
2] and play a critical role in the development of this air-
way disease  [3, 4] . Both cytokines alter the structural in-
tegrity of the airways, leading to an exaggerated response 
to a variety of stimuli  [5] . An increased smooth muscle 
mass and altered contractile properties of airway smooth 
muscle cells (ASMC) contribute to the altered responsive-
ness of the airways  [6] . This alteration of the ASMC con-
tractile response can result from a multitude of mecha-
nisms such as changes in cell surface receptors, modifica-
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 Abstract 
 Background: The interleukins IL-4 and IL-13 play a key role in 
the pathophysiology of asthma. The interleukin receptor IL-
13R  2 is believed to act as a decoy receptor, but until now, 
the functional significance of IL-13R  2 remains vague.  Meth-
ods: Bronchial reactivity was quantified in murine lung slices 
by digital video microscopy and acetylcholine (ACH)-in-
duced Ca 2+  signaling was measured in human airway smooth 
muscle cells (ASMC) using fluorescence microscopy.  Results: 
IL-4 or IL-13 up to 50 ng/ml induced bronchial hyperreactiv-
ity. But after incubation with 100 ng/ml this effect was lost 
and bronchial responsiveness was again comparable to the 
control level. The effects of IL-4 and IL-13 on bronchial reac-
tivity were paralleled by the effects on ASMC proliferation. 
Fifty nanograms per milliliter of IL-4 and IL-13 increased the 
Ca 2+  response of human ASMC to ACH. At 100 ng/ml, how-
ever, the effects of the cytokines on the Ca 2+  response were 
no longer evident. The expression of IL-13R  2 increased with 
increasing concentrations of IL-4 or IL-13, reaching its maxi-
mum at 100 ng/ml. Blocking IL-13R  2, the loss of the effect 
of IL-4 and IL-13 at 100 ng/ml on human ASMC proliferation 
and the ACH-induced Ca 2+  response were no longer present. 
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tion of intracellular signaling molecules or changes in the 
properties of the contractile apparatus. Cytokines have 
been found to directly act on ASMC, changing ASMC 
contractile properties and potentially leading to BHR. 
Reports using animal models of asthma show the poten-
tial role of IL-13 in the development of BHR  [7–9] . Ven-
kayya et al.  [10] presented data implying that IL-4 and 
IL-13 can induce BHR in mice even in the absence of mast 
cells, B or T lymphocytes. In mouse tracheal rings, pre-
treatment with IL-13 increased carbachol-induced maxi-
mum force generation  [11] and in rabbit tracheal smooth 
muscle, IL-13 increased acetylcholine (ACH)-induced 
contractility  [12] . However, the mechanisms by which 
cytokines promote proasthmatic responses in ASMC 
have not been clearly established.
 Calcium is a common second messenger molecule and 
has a central role in regulating the contractile function of 
ASMC. Cytokines such as tumor necrosis factor   or IL-
13 have been shown to augment agonist-induced ASMC 
contractility by enhancing agonist-evoked Ca 2+  tran-
sients to a variety of contractile agonists  [13–15] . On the 
other hand, Madison and Ethier  [16] found no effect of 
50 ng/ml IL-13 on carbachol-induced Ca 2+  transients in 
ASMC and reported that 50 ng/ml IL-4 even diminished 
these Ca 2+  transients. Thus, the role of cytokines in the 
Ca 2+  homeostasis of ASMC is still controversial.
 ASMC express the interleukin-binding proteins IL-
4R  , IL-13R  1 and IL-13R  2  [17, 18] . IL-4 and IL-13 act 
through the type II receptor that consists of a dimer of 
the IL-4R  and the IL-13R  1 proteins. Upon the binding 
of IL-4 or IL-13, the type II receptor activates the signal 
transducer and activator of transcription 6 (STAT-6) sig-
naling cascade [for a review see  19 ]. IL-13R  2 is believed 
to be a decoy receptor that is not capable of initiating sig-
naling pathways. However, in glioblastoma cells, Raha-
man et al.  [20] showed that IL-13R  2 inhibited IL-4-me-
diated STAT-6 activation via its cytoplasmic domain, 
probably by interaction with IL-4R  . Only recently, Syed 
et al.  [21] reported that in cultured human ASMC, IL-13 
transcriptionally upregulated IL-13R  2, but the func-
tional significance of this finding remained unknown. 
Until now, however, there are no data demonstrating a 
limitation or even reversal of the effects of Th2 cytokines 
on BHR, leaving the role of IL-13R  2 vague.
 In our study, we show that IL-4 and IL-13 directly alter 
ASMC responsiveness by enhancing ACH-induced con-
tractility and Ca 2+  signaling. Furthermore, we provide 
evidence that IL-13R  2 in fact functions to regulate the 
effects of IL-4 and IL-13, forming a signaling mechanism 
of protection against the effects of these cytokines.
 Materials and Methods 
 Cell culture reagents were obtained from Life Technologies 
(Eggenstein, Germany). Other reagents were bought from Sigma-
Aldrich (Deisenhofen, Germany) unless stated otherwise. Balb/C 
mice were purchased from Harlan-Winkelmann (Borchen, Ger-
many). All procedures were approved by the Ethics Committee of 
the Ludwig Maximilian University in Munich.
 Lung Slices 
 Lung slices were prepared as described before  [22] . Briefly, 
Balb/C mice (42–77 days old) were sacrificed by an intraperito-
neal injection of phenobarbital and the chest wall was removed. 
The trachea was cannulated using an intravenous catheter and the 
lungs were inflated with 2% agarose-sHBSS at 37  °  C. Subsequent-
ly, 0.1–0.2 ml of air was injected to flush the agarose-sHBSS out of 
the airways and the agarose was gelled by placing the mouse prep-
aration at 4  °  C. The lungs were removed, embedded in 2% agarose-
sHBSS and slices of   200   m thickness were cut with an EMS-
4000 tissue slicer (Electron Microscopy Sciences, Fort Washing-
ton, Pa., USA). The slices were maintained by floating them in 
DMEM supplemented with antibiotics and antimycotics at 37  °  C 
in 5% CO 2  for up to 5 days. In culture, lung slices maintain their 
contractile properties for up to 5 days  [22] . Experiments were 
therefore performed between day 2 and 5 of cultivation. The slices 
were incubated with varying concentrations of recombinant mu-
rine IL-13 or IL-4 (R&D Systems, Minneapolis, Minn., USA) for 
24 h. Each slice was only used for one experiment. For each group 
of experiments, slices from at least 4 different mice were used. To 
measure the airway cross-sectional area, lung slices were placed in 
culture dishes immersed in sHBSS and held in position by a piece 
of a nylon mesh. Phase-contrast images were recorded using a dig-
ital CCD camera (AxioCam MRm; Carl Zeiss Vision, Munich, 
Germany). Frames were captured in time lapse (1 frame/s) and the 
cross-sectional area of the airway was measured by pixel summing 
using the Scion image analysis software (Scion Corporation, Fred-
erick, Md., USA). Contraction velocity was defined as maximal 
change in cross-sectional area per second.
 Immunohistochemistry 
 To perform the immunohistochemical analysis, lung slices 
were cut   500   m thick with a scalpel blade and incubated for 
24 h at 37  °  C in 5% CO 2  with varying concentrations of murine 
IL-4 and IL-13. The fixed tissue samples were dehydrated through 
a graded series of ethanol and embedded in paraffin. Sections of 
4   m thickness were cut with a Leica SM 2000 R microtome (Lei-
ca Instruments, Nussloch, Germany) and mounted on glass slides. 
After deparaffinization, endogenous peroxidase activity was 
blocked with 10% H 2 O 2  in methanol for 20 min at room temper-
ature. IL-4R  , IL-13R  1 and IL-13R  2 immunoreactivity was lo-
calized with monoclonal rat anti-mouse IL-4R  , goat anti-hu-
man IL-13R  1 and goat anti-mouse IL-13R  2 antibodies (dilu-
tion 1:  100; R&D Systems, Minneapolis, Minn., USA). After the 
addition of a biotin-conjugated secondary antibody (dilution
1:  200; donkey anti-goat IgG or chicken anti-rat IgG), the sections 
were incubated with an avidin-D-horseradish peroxidase com-
plex (Vectastain ABC kit; Vector Laboratories, Burlingame, Ca-
lif., USA) and exposed to 0.1% diaminobenzidine-tetrahydro-
chloride and 0.05% H 2 O 2  as a source of peroxidase substrate. Each 
section was counterstained with hematoxylin. Incubation with-
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out the primary antibody served as negative control. The average 
length of the basement membrane of the airways in the sections 
was 140  8 10   m without significant differences between the ex-
perimental groups.
 After the incubation with the appropriate antibodies, images 
of lung sections were taken using a CCD camera. Subsequently, 
the maximum thickness of the ASMC layer and the number of 
nuclei in the ASMC layer in each airway of the stained sections 
were assessed. In representative ASMC, regions of interest (ROI) 
were set and the labeling was quantified by measuring the mean 
density of the ROI using the Scion image analysis software. The 
immunohistochemical analysis was performed in a blinded fash-
ion. All values are expressed as percentage of the control groups 
(no incubation with interleukins).
 Proliferation of Human ASMC 
 Human ASMC (primary cultures; Cambrex Bio Science, 
Walkersville, Md., USA) were grown as monolayer cultures and 
incubated with varying concentrations of recombinant human 
IL-4 or IL-13 (R&D Systems, Minneapolis, Minn., USA) during 
the exponential phase of the cell growth. After 24 h of incubation, 
the cell number of each culture was assessed.
 Ca 2+  Signaling in ASMC 
 To evaluate the effects of interleukins on ACH-induced Ca 2+  
signaling, human ASMC were incubated for 24 h with IL-4 or IL-
13. Subsequently, the ASMC were loaded for 45 min at 37° with 
the calcium indicator dye Oregon green (10   M ; Molecular Probes, 
Eugene, Oreg., USA) in sHBSS containing 0.2% Pluronic F-127 
(Calbiochem, La Jolla, Calif., USA). After loading, ASMC were 
incubated for at least 45 min in sHBSS to allow for complete dye 
de-esterification and then examined with a fluorescence micro-
scope (Axiovert 200 M; Carl Zeiss, Jena, Germany). Images were 
recorded in time lapse (1 frame/s) using a digital CCD camera 
(AxioCam MRm; Carl Zeiss Vision, Munich, Germany). For each 
image, ROI were defined in single ASMC, and the average fluo-
rescence intensity of each ROI was measured. Final fluorescence 
values were expressed as a fluorescence ratio (F/F 0 ) normalized 
to the initial fluorescence (F 0 ). Each analysis was performed using 
custom-written macros in Scion.
 Statistics 
 One-way ANOVA or ANOVA on ranks (combined with pair-
wise multiple comparisons) were performed using the Sigma Stat 
software (Jandel Scientific, Chicago, Ill., USA). A p value of less 
than 0.05 was considered statistically significant.
 Results 
 Influence of IL-4 and IL-13 on Bronchial Reactivity 
 To evaluate the dependence of bronchial reactivity on 
varying concentrations of cytokines, lung slices were in-
cubated with increasing concentrations of IL-4 and IL-13 
and exposed to 1   M ACH; the contraction (the maximal 
decrease in cross-sectional area) as well as the velocity of 
contraction (the maximal change in cross-sectional area 
per second) were quantified using digital video micros-
copy ( fig. 1 , see online supplement for the corresponding 
video at www.karger.com/doi/10.1159/000097022). Be-
fore experiments with interleukins were performed, the 
baseline bronchial reactivity of the airways in the lung 
slices without IL-4 or IL-13 was evaluated. Without incu-
bation with interleukins, the airways contracted by   30% 
of the baseline cross-sectional area in response to 1   M 
ACH; the contraction velocity was 3.24   m 2 /s (n = 21). 
These values served as reference (control) for the subse-
quent experiments and were set to 100%. Following in-
cubation with IL-13 for 24 h, ACH-induced contraction 
 Fig. 1. ACH-induced airway contraction in lung slices.  The phase-
contrast micrographs show an airway in a lung slice after 24 h of 
incubation with 50 ng/ml IL-13 immediately before ( a ) and 150 s 
after ( b ) the addition of 1   M ACH. Scale bar = 10   m. See online 
supplement for the corresponding video at www.karger.com/doi/ 
10.1159/000097022. 
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increased with increasing concentrations of IL-13 with 
the maximal contraction (275% of controls, n = 11, p  ! 
0.01;  fig. 2 a) and contraction velocity (304%, p  ! 0.01; 
 fig. 2 b) being reached after incubation with 50 ng/ml IL-
13. However, following incubation with 100 ng/ml IL-13 
for 24 h, contraction and contraction velocity were both 
reduced compared to the lower concentrations of IL-13
(n = 23, p  ! 0.01 vs. 50 ng/ml IL-13) and showed no sig-
nificant differences compared to the control group (con-
traction: 124% of controls; velocity: 151% of controls).
 Similarly, following incubation with 50 ng/ml IL-4 for 
24 h, ACH-induced contraction increased to 178% and 
contraction velocity to 269% (n = 29, p  ! 0.01;  fig. 3 ). In-
cubation with 100 ng/ml IL-4 for 24 h resulted in a lower 
contraction and contraction velocity compared to 50 ng/
ml IL-4 and no longer showed significant differences 
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 Fig. 2. Effects of IL-13 on bronchial reactivity.  After incubation 
with IL-13 for 24 h, airways in lung slices were exposed to 1   M 
ACH and the maximal decrease in cross-sectional area as well as 
the velocity of contraction were quantified using digital video mi-
croscopy. Up to 50 ng/ml, incubation with IL-13 increased con-
traction ( a ) as well as contraction velocity ( b ). But after incuba-
tion with 100 ng/ml IL-13, both values were again comparable to 
the control group. n = 11–23.  *  p  ! 0.01 versus 0 and 100 ng/ml. 
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 Fig. 3. Effects of IL-4 on bronchial reactivity. After  incubation 
with IL-4 for 24 h, airways in lung slices were exposed to 1   M 
ACH and the maximal decrease in cross-sectional area as well as 
the velocity of contraction were quantified. Incubation with 
50 ng/ml IL-4 increased contraction ( a ) and contraction velocity 
( b ). Once more, after incubation with 100 ng/ml IL-4, both pa-
rameters were again similar to the control group. n = 10–29.  * p  ! 
0.01 versus 0 and 100 ng/ml. 
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compared to the control group (contraction: 121% of con-
trols; velocity: 142% of controls; n = 10, p  ! 0.01 vs. 50 ng/
ml IL-4). Comparing the effects of 50 ng/ml IL-4 with 
50 ng/ml IL-13, the contraction induced by IL-13 was sig-
nificantly higher (p  ! 0.01), while the contraction veloc-
ity was not different. Because the maximal contraction 
and contraction velocity were observed with 50 ng/ml IL-
4 or IL-13 and both contraction and contraction velocity 
decreased with 100 ng/ml of the cytokines, these concen-
trations were used in the following experiments.
 Effects of IL-4 and IL-13 on ASMC Proliferation 
 To investigate the effects of IL-4 and IL-13 on the 
ASMC mass, the thickness of the ASMC layer and the 
number of ASMC nuclei in lung sections were quantified 
( fig. 4 ). To compensate for the different airway sizes, both 
parameters were divided by the length of the basement 
membrane of the respective airway. Fifty nanograms per 
milliliter IL-4 and 50 ng/ml IL-13 caused a significant 
thickening of the ASMC layer (IL-4: 214% of controls; IL-
13: 207% of controls; n = 8–13, p  ! 0.01;  fig. 5 a). After 
incubation with 100 ng/ml IL-4 or 100 ng/ml IL-13, the 
thickness of the ASMC layer was found to be comparable 
to the control group (100 ng/ml IL-4: 124% of controls; 
100 ng/ml IL-13: 121% of controls; p  ! 0.01 vs. 50 ng/ml). 
The number of ASMC nuclei showed a similar pattern, 
increasing after incubation with 50 ng/ml (IL-4: 211% of 
controls; IL-13: 245% of controls; n = 8–13, p  ! 0.001; 
 fig. 5 b) and decreasing to starting level after 100 ng/ml 
(IL-4: 154% of controls; IL-13: 153% of controls; p  ! 0.001 
vs. 50 ng/ml).
 In human primary ASMC cultured as monolayer, in-
cubation with 50 ng/ml IL-4 or IL-13 for 24 h also in-
duced an increase in cell number (IL-4: 168% of controls; 
IL-13: 165% of controls; n = 6, p  ! 0.05;  fig. 6 ). Similarly 
to murine ASMC in lung slices, the cell numbers returned 
to starting levels after incubation with 100 ng/ml of each 
interleukin (IL-4: 106% of controls; IL-13: 95% of con-
trols; p  ! 0.05 vs. 50 ng/ml).
 Effects of IL-4 and IL-13 on ACH-Induced Ca 2+  
Signaling in ASMC 
 The rise in intracellular calcium is an essential event 
in the signaling cascade leading to ASMC contraction. 
We therefore investigated the effects of IL-4 and IL-13 
on ACH-induced Ca 2+  signaling. Human ASMC were 
loaded with the Ca 2+  indicator dye Oregon green and 
examined with fluorescence microscopy. The Ca 2+  re-
sponse to ACH consisted of an initial Ca 2+  transient fol-
lowed by a Ca 2+  plateau ( fig. 7 a). Without incubation 
 Fig. 4. Effects of IL-13 on ASMC and IL-13R  2 expression. Lung 
slices were incubated with 50 ng/ml IL-13 for 24 h, embedded in 
paraffin and exposed to an IL-13R  2 antibody followed by a bio-
tin-conjugated secondary antibody. Counterstaining was per-
formed with hematoxylin.  a Control sections without incubation 
with IL-13 showed weak staining for the IL-13R  2 receptor.  b Af-
ter incubation with 50 ng/ml IL-13, the thickness of the ASMC 
layer (double-head arrows) as well as the number of ASMC nuclei 
were increased and the staining for IL-13R  2 was intensified. 
 ! 40. 
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 Fig. 5. Effects of IL-4 and IL-13 on ASMC in lung slices. Lung 
slices were incubated with IL-4 or IL-13 for 24 h, embedded in 
paraffin, stained with hematoxylin and eosin, and the thickness 
of the ASMC layer, the number of ASMC nuclei and the length of 
the basement membrane were quantified for each airway. To com-
pensate for the different airway sizes, the thickness of the ASMC 
layer and the number of ASMC nuclei were divided by the length 
of the basement membrane of the respective airway. BM = Base-
ment membrane.  a Incubation with 50 ng/ml IL-4 or 50 ng/ml 
IL-13 caused a considerable thickening of the ASMC layer. But 
after incubation with 100 ng/ml, the thickness of the ASMC layer 
was again similar to the control group. n = 8–13.  *  p  ! 0.01.  b The 
number of ASMC nuclei showed a similar pattern with an in-
crease after 50 ng/ml and a decrease after 100 ng/ml. n = 8–13.
 * p  ! 0.001. 
 Fig. 6. Effects of IL-4 and IL-13 on proliferation of human ASMC 
monolayer cultures. In human primary ASMC, incubation with 
50 ng/ml IL-4 or IL-13 for 24 h induced an increase in cell number. 
Similarly to murine ASMC in lung slices, the cell numbers re-
turned to starting levels after incubation with 100 ng/ml. n = 6.
 * p  ! 0.05. 
 Fig. 7. Effects of IL-4 and IL-13 on the ACH-induced Ca 2+  signal-
ing in ASMC. Human ASMC were loaded with the Ca 2+  indicator 
Oregon Green and examined with fluorescence microscopy.
 a The Ca 2+  response to ACH (arrow) consisted of an initial Ca 2+  
transient followed by a Ca 2+  plateau as shown by the representa-
tive trace.  b After incubation with 50 ng/ml IL-4 or IL-13 for 
24 h, the magnitude of the initial Ca 2+  transient was increased 
compared to the control group. When incubating with 100 ng/ml 
IL-4 or IL-13, the magnitude of the initial Ca 2+  transient was re-
duced and no longer showed significant differences compared to 
the control group. n = 34–43 cells.  * p  ! 0.05 versus 0 ng/ml;
 * *  p  ! 0.01 versus 50 ng/ml. 
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with interleukins, the magnitude of the initial Ca 2+  
transient (the difference in percent between F/F 0  mea-
sured immediately before and at the maximum value of 
the Ca 2+  transient) was 43% above baseline values (n = 
57 cells). These values served as reference (control) for 
the subsequent experiments and were set to 100%. After 
incubation with 50 ng/ml IL-13 for 24 h, the magnitude 
of the initial Ca 2+   transient was increased compared to 
the control group (128% of controls; p  ! 0.05;  fig. 7 b). 
When incubated with 100 ng/ml IL-13, the magnitude 
of the initial Ca 2+  transient was reduced and no longer 
different from the of the control group (85% of controls; 
p  ! 0.01 vs. 50 ng/ml IL-13). Incubation with 50 ng/ml 
IL-4 for 24 h also augmented the ACH-induced Ca 2+  re-
sponse (132% of controls; p  ! 0.05;  fig. 7 b). Again, incu-
bation with 100 ng/ml IL-4 resulted in a lower magni-
tude of the initial Ca 2+  transient (68% of controls; p  ! 
0.01 vs. 50 ng/ml IL-4).
 Effects of IL-4 and IL-13 on Interleukin Receptor 
Expression 
 To test if changes in the interleukin receptor expres-
sion caused the lack of effectiveness of IL-4 and IL-13 at 
100 ng/ml, we performed immunohistochemistry with 
antibodies specific for the IL-4R  , IL-13R  1 and IL-
13R  2 proteins in lung slices. Subsequently, the staining 
of the ASMC was quantified using the Scion image anal-
ysis software.
 Incubation with 50 ng/ml IL-4 or IL-13 increased the 
expression of IL-4R  (IL-4: 186% of controls; IL-13: 203% 
of controls; n = 8–13, p  ! 0.01;  fig. 8 ). Incubation with 
100 ng/ml IL-4 or IL-13 had no further effect.
 Fig. 8. Effects of IL-4 and IL-13 on the expression of IL-4R  . Lung 
slices were incubated for 24 h with IL-4 or IL-13, embedded in 
paraffin and labeled with an IL-4R  antibody. Staining of ASMC 
was quantified using the Scion image analysis software. Incuba-
tion with IL-4 ( a ) or IL-13 ( b ) increased the expression of IL-4R  
in ASMC. No concentration dependence could be observed. n = 
8–13.  * p  ! 0.01 versus 0 ng/ml. 
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 Fig. 9. Effects of IL-4 and IL-13 on the expression of IL-13R  1. 
Incubation with IL-4 ( a ) or IL-13 ( b ) for 24 h increased the expres-
sion of IL-13R  1 in ASMC. These effects were not concentration 
dependent. n = 8–13.  * p  ! 0.01 versus 0 ng/ml.  
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 Incubation with 50 ng/ml IL-4 or IL-13 increased the 
expression of IL-13R  1 (IL-4: 198% of controls; IL-13: 
202% of controls; n = 8–13, p  ! 0.01;  fig. 9 ). Again, incu-
bation with 100 ng/ml IL-4 or IL-13 had no additional 
effect.
 In contrast, the expression of IL-13R  2 increased in a 
concentration-dependent manner after incubation with 
IL-4 or IL-13 (100 ng/ml IL-4: 244% of controls; 100 ng/
ml IL-13: 134% of controls; n = 8–13, p  ! 0.01;  fig. 10 ).
 Effects of IL-13R  2 Inhibition 
 Syed et al.  [21] reported a 1.6-fold upregulation of IL-
13R  2 in response to 100 ng/ml IL-13 and our data on the 
expression of IL-13R  2 suggested an involvement in the 
lack of effectiveness of IL-4 and IL-13 at 100 ng/ml. To 
further test this hypothesis, we used an anti-IL-13R  2 
antibody to block IL-13R  2. Because of the specificity of 
this antibody for the human IL-13R  2, only its effect on 
human ASMC could be assessed. After incubation with 
4   g/ml of the IL-13R  2 antibody, the decrease in ASMC 
proliferation after 100 ng/ml IL-4 or IL-13 was no longer 
evident (100 ng/ml IL-4 + IL-13R  2 antibody: 181% of 
controls; 100 ng/ml IL-13 + IL-13R  2 antibody: 177% of 
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and IL-13-treated ASMC. In human primary cultured ASMC, the 
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 Fig. 12. Effect of IL-13R  2 inhibition on the ACH-induced Ca 2+  
signaling of IL-4- and IL-13-treated human ASMC. In human 
primary cultured ASMC, the decrease in the ACH-induced Ca 2+  
transient after incubation with 100 ng/ml IL-4 or IL-13 compared 
to 50 ng/ml was reversed when treated with a human anti-IL-
13R  2 antibody. n = 34–43 cells.  * p  ! 0.05 versus 0 and 100 ng/
ml. 
Interleukin (ng/ml)
0
50
100
150
200
250
100 +
IL-13 R2 antibody
* *
0
* *
50 100
C
el
l n
um
b
er
 (%
 c
on
tr
ol
s)
IL-13
IL-4
Interleukin (ng/ml)
Fl
uo
re
sc
en
ce
 in
cr
ea
se
 (%
 c
on
tr
ol
s)
0
20
40
60
80
100
120
140
160
180
200
100 +
IL-13R2 antibody
*
*
0
* *
50 100
IL-13
IL-4
 11 
 12 
 IL-13R  2 Reverses the Effects of IL-13 
and IL-4 
Int Arch Allergy Immunol 2007;142:199–210 207
controls; n = 6, p  ! 0.05 vs. 0 and 100 ng/ml;  fig. 11 ). Re-
garding the ACH-induced Ca 2+  mobilization, incubation 
with the IL-13R  2 antibody completely inhibited the de-
crease observed after the incubation with 100 ng/ml IL-4 
or IL-13 (100 ng/ml IL-4 + IL-13R  2 antibody: 136% of 
controls; 100 ng/ml IL-13 + IL-13R  2 antibody: 167% of 
controls; n = 34–43 cells, p  ! 0.05 vs. 0 and 100 ng/ml; 
 fig. 12 ).
 Discussion 
 In this study, we showed that IL-4 or IL-13 in concen-
trations up to 50 ng/ml induced BHR in murine lung slic-
es in terms of both increased contraction and contraction 
velocity. But after incubation with 100 ng/ml this effect 
was lost and bronchial responsiveness was again compa-
rable to the control level. The effects of IL-4 and IL-13 on 
bronchial reactivity were paralleled by the effects on 
ASMC proliferation. Furthermore, IL-4 and IL-13 in-
creased the Ca 2+  response of human ASMC to ACH. 
Again, at 100 ng/ml the effects of the cytokines on the 
Ca 2+  response were no longer evident. IL-4 and IL-13 in-
creased the expression of IL-4R  and IL-13R  1 in ASMC 
with the expression being comparable after incubation 
with 50 or 100 ng/ml. In contrast, the expression of IL-
13R  2 increased with increasing concentrations of IL-4 
or IL-13, reaching its maximum at 100 ng/ml. When 
blocking IL-13R  2, the loss of effect of IL-4 and IL-13 at 
100 ng/ml on the ASMC proliferation and the ACH-in-
duced Ca 2+  response was no longer evident. This pattern 
of findings suggests that IL-4 and IL-13 induce BHR by 
changing the Ca 2+  homeostasis of ASMC and that these 
effects are regulated by IL-13R  2, constituting a protec-
tive mechanism against the effects of the proinflamma-
tory cytokines known to be involved in asthma.
 In bronchoalveolar lavage samples from patients with 
atopic asthma, the number of activated Th2 lymphocytes 
 [23] , derived from CD4+ T lymphocytes  [24] , is increased 
and Th2 lymphocytes appear to be critically important 
for the pathophysiological events leading to asthma  [25, 
26] . Furthermore, IL-13 released by Th2 lymphocytes  [1, 
2] was identified to be a crucial participant in the allergic 
responses of the respiratory tract  [3, 4] . Although numer-
ous studies also noticed a role for IL-4 in asthma  [27, 28] , 
other reports suggested that IL-4 was not obligatory for 
this airway disease  [29, 30] . In the present study, we aimed 
at examining the effects of both IL-4 and IL-13 on bron-
chial reactivity as well as on ASMC Ca 2+  signaling and at 
investigating how these effects might be regulated.
 We used murine lung slices to investigate the agonist-
induced contractility of ASMC. Lung slices have previ-
ously been used by us and others to study a variety of 
responses including bronchial contractility  [22, 31–35] , 
vascular responses  [36] and mucociliary function  [37] . 
The major advantage of this approach is that the in situ 
organization of the lung tissue and the contractility of the 
ASMC are maintained for several days. Thus, murine 
lung slices in combination with video microscopy appear 
to be particularly suited to study bronchial reactivity in 
vitro. The culture of human lung slices was established 
by Wohlsen et al.  [38] , using material obtained after lung 
or lobe resections. Unfortunately, patients undergoing 
lung resections due to malignant diseases, i.e. the major-
ity of these patients, for the most part suffer from chron-
ic obstructive airway disease.Under these conditions, the 
investigation of BHR would have been impaired. To cir-
cumvent this drawback, we investigated the influence of 
IL-4 and IL-13 on ACH-induced Ca 2+  signaling using 
primary cultured human ASMC that were obtained post 
mortem from donors without lung diseases. With this ap-
proach, we were able to combine information obtained 
with murine ASMC in lung slices with data acquired with 
primary cultured human ASMC.
 To assess BHR, we used two parameters: maximal 
contraction and contraction velocity. Duguet et al.  [39] 
analyzed bronchial reactivity among inbred mouse 
strains in vivo and in vitro and found that the contraction 
velocity of lung slices correlated with the bronchial reac-
tivity in vivo, whereas contraction did not. In a previous 
paper, we also analyzed contraction and contraction ve-
locity in the mouse strains that Duguet et al.  [39] used 
and found both measures to be closely related and to give 
identical readings of BHR  [32] . In this study, IL-4 and IL-
13 also showed comparable effects on contraction and 
contraction velocity. A possible explanation for these dif-
ferences might be the thickness of the slices used, which 
was 0.5–1 mm in the study by Duguet et al.  [39] compared 
to 200   m in our studies. Differences in smooth muscle 
mass and its surface-to-volume ratio might have led to 
the differences in the mechanical contraction proper-
ties.
 After incubation with IL-4 and IL-13, we found the 
thickness of the ASMC layer to be increased. An increased 
ASMC mass alone could have accounted for the elevated 
maximal airway contraction. However, the contraction ve-
locity was also increased after incubation with the inter-
leukins and this finding pointed towards intrinsic altera-
tions in the contractile properties of the ASMC. An in-
creased ASMC mass could have resulted from an increase 
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in cell size, leaving the number of ASMC unchanged. Al-
ternatively, cell proliferation with increased cell numbers 
could have been the cause of the thickening of the ASMC 
layer. Evaluating the number of nuclei in the ASMC layers 
in lung slices and the cell numbers of cultured human 
ASMC under the influence of IL-4 and IL-13, we found 
that indeed ASMC proliferation rather than an increase in 
cell size accounted for the increase in ASMC mass.
 Calcium is a ubiquitous signaling molecule that is in-
volved in the regulation of a broad variety of cellular 
events in almost all mammalian cell types  [40–42] . In 
ASMC, the elevation of [Ca 2+ ] c  leads to contraction. In 
our study, we found an enhanced Ca 2+  response to ACH 
in human ASMC treated with 50 ng/ml IL-13 or IL-4. But 
incubation with 100 ng/ml IL-13 or IL-4 attenuated the 
ACH-induced Ca 2+  signaling and this pattern of response 
paralleled the effects of IL-4 and IL-13 on ASMC contrac-
tion in murine lung slices. Furthermore, this concentra-
tion dependence was also found for the effects on the pro-
liferation of both murine and human ASMC. Therefore, 
the attenuation of the effects of IL-4 and IL-13 at high 
concentrations does not appear to depend on the culture 
form nor to be species specific.
 Deshpande et al.  [14] reported enhanced intracellular 
Ca 2+  responses to bradykinin, thrombin and histamin in 
IL-13-treated human ASMC. Tliba et al.  [11] showed an 
increase in force generation induced by both carbachol 
and KCl in murine cultured tracheal rings pretreated 
with 100 ng/ml IL-13 . The same group noticed that in 
cultered human ASMC, 50 ng/ml IL-13 significantly en-
hanced the calcium signals induced by bradykinin, his-
tamine and carbachol. These findings are in agreement 
with our results. In contrast, Madison and Ethier  [16] no-
ticed no effect of 50 ng/ml IL-13 and even an inhibitory 
effect of 50 ng/ml IL-4 on calcium transients in response 
to carbachol in bovine ASMC. The most obvious meth-
odological difference is the use of bovine ASMC by Mad-
ison and Ethier  [16] compared to murine and/or human 
ASMC used by our group, Deshpande et al.  [14] and Tli-
ba et al.  [11] . Although our data suggest comparable pat-
terns of response to IL-4 and IL-13 in murine and human 
ASMC, the effects of these cytokines may be different in 
bovine tissue.
 The data reported in this paper demonstrate that both 
cytokines, IL-13 and IL-4, possess the potential to in-
crease the contractile responses of ASMC to ACH and to 
augment ACH-induced Ca 2+  signaling. These effects oc-
curred at cytokine concentrations up to 50 ng/ml. When 
incubating lung slices or human ASMC with 100 ng/ml 
IL-13 or IL-4, these effects were no longer evident, indi-
cating some kind of negative feedback mechanism. One 
possible mechanism would have been the up- or down-
regulation of interleukin receptors. IL-4 and IL-13 bind to 
the type II receptor consisting of a dimer of the IL-4R  
and the IL-13R  1 proteins. Upon binding, both interleu-
kins affect gene transcription via the STAT-6 pathway. 
Myrtek et al.  [43] reported that in peripheral blood eo-
sinophils, IL-13 and IL-4 downregulate IL-13R  1 expres-
sion. The downregulation of IL-4R  and/or IL-13R  1 
would have been one possible mechanism underlying the 
negative feedback on BHR and Ca 2+  signaling observed in 
our study. However, there was no decrease in the labeling 
for IL-4R  or IL-13R  1 with increasing concentrations of 
IL-4 or IL-13, rendering this possibility unlikely. In con-
trast, the expression of IL-13R  2, which is believed to act 
as a decoy receptor, increased in a concentration-depen-
dent manner after incubation with IL-4 and IL-13. Zheng 
et al.  [44] demonstrated that IL-4 and IL-13 can upregu-
late IL-13R  2 expression in murine epithelial cells. In 
ASMC, the regulation of genes by interleukins has been 
studied using microarray techniques  [45, 46] and  Syed et 
al.  [21] only recently found that IL-13 increases IL-13R  2 
gene expression although the physiological significance of 
this finding remained unknown. In agreement with these 
data, our results show that IL-13 and IL-4 have the poten-
tial to upregulate IL-13R  2. Because of the correlation be-
tween the decrease of BHR and Ca 2+  signaling at 100 ng/
ml IL-4 or IL-13 and the high expression of IL-13R  2 at 
this cytokine concentration, IL-13R  2 appears to nega-
tively control the effects of IL-13 and IL-4. To further test 
the hypothesis that IL-13R  2 is involved in the limitation 
or even reversal of the effects of Th2 cytokines, IL-13R  2 
was blocked in IL-4- and IL-13-treated human ASMC 
with a human anti-IL-13R  2 antibody. Because, to our 
knowledge, there is no murine antibody, IL-13R  2 could 
not be blocked in the experiments on BHR in lung slices. 
However, blocking IL-13R  2 in human ASMC reversed 
the decrease in ASMC proliferation and ACH-induced 
Ca 2+  signaling observed at 100 ng/ml IL-4 and IL-13. Our 
data therefore demonstrate for the first time that IL-13R  2 
acts as a negative regulator in IL-4- and IL-13-mediated 
signal transduction.
 Debinski et al.  [47] and Murata et al.  [48] reported that 
IL-4 does not bind to IL-13R  2. But our data suggest that 
IL-13R  2 also functions as a negative controller for the 
IL-4 signaling pathway. Whether IL-4 directly binds to 
IL-13R  2 or forms an additional signaling complex using 
a second molecule yet has to be studied.
 Taken together, we have shown that IL-13 and IL-4 in-
duce BHR and that both interleukins elevate ACH-in-
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duced intracellular Ca 2+  mobilization. We have – to our 
knowledge for the first time – demonstrated that the ef-
fects of IL-4 and IL-13 underlie a control mechanism at 
high concentrations and that this mechanism is mediated 
by IL-13R  2. We believe that our findings contribute to 
a better understanding of the relevance of IL-13R  2, 
which might be a protective function by regulating IL-13- 
and IL-4-mediated signal transduction and thereby lim-
iting pathological alterations in Th2-mediated inflam-
matory diseases.
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